Akums Drugs

{
  "main_header": {
    "sid": 10039335,
    "name": "Akums Drugs",
    "stock_name": "Akums Drugs",
    "full_name": "Akums Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/akums-drugs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "449.20",
    "chg": 10.4,
    "chgp": "2.37%",
    "dir": 1,
    "prev_price": "438.80",
    "mcapval": "6,976.00 Cr",
    "mcap": "Small Cap",
    "scripcode": "544222",
    "symbol": "AKUMS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE09XN01023",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.36 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/akums-drugs-10039335-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-pharmaceuticals-ltd-fallingrising-3815183",
        "imagepath": "",
        "date": "2026-02-02 00:57:21",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Akums Drugs has outperformed its sector and the Sensex benchmark in the short term. Over the past week, the stock appreciated by 4.90%, while the Sensex declined by 1.00%. Year-to-date, the stock has marginally declined by 1.99%, yet this is still better than the Sensex's 5.28% fall. The stock's intraday high on 01-Feb reached ₹454.95, a 3.35% increase from the previous close, signalling strong buying interest during the session.</p>\n<p>Notably, the stock has been trading above its 5-day, 20-day, and 50-day moving averages, indicating positive short- to medium-term momentum. However, it remains below its 100-day and 200-day moving averages, suggesting that longer-term trends have yet to fully turn bullish. Liquidity remains adequate..."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3814117",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AkumsDrugsPharm_mojoScore_3814117.png",
        "date": "2026-02-01 10:10:22",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Faces Technical Momentum Shift Amid Bearish Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-faces-technical-momentum-shift-amid-bearish-signals-3805033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AkumsDrugsPharm_technicaldot_3805033.png",
        "date": "2026-01-27 08:03:44",
        "description": "Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some mildly bullish signals on weekly MACD and KST indicators, the overall technical landscape remains cautious, reflecting the stock’s underperformance relative to the broader market and sector benchmarks."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3798128",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AkumsDrugsPharm_mojoScore_3798128.png",
        "date": "2026-01-21 10:10:53",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 21 January 2026, providing investors with the latest view of the stock’s position."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3787953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AkumsDrugsPharm_mojoScore_3787953.png",
        "date": "2026-01-10 10:10:49",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3774754",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AkumsDrugsPharm_mojoScore_3774754.png",
        "date": "2025-12-30 10:10:31",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals: Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3766584",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AkumsDrugsPharm_technicaldot_3766584.png",
        "date": "2025-12-23 08:18:58",
        "description": "Akums Drugs & Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent price movements and technical parameters suggest a transition from a mildly bearish stance to a more sideways trend, highlighting a period of consolidation amid fluctuating investor sentiment."
      },
      {
        "title": "Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-negative-financial-trends-3763713",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AkumsDrugs_mojoScore_3763713.png",
        "date": "2025-12-19 10:10:20",
        "description": "Akums Drugs has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. The pharmaceutical company’s recent assessment highlights a complex interplay of valuation appeal, financial pressures, and technical signals, set against a backdrop of subdued sector performance and market capitalisation constraints."
      },
      {
        "title": "Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-negative-financial-trends-3735195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugs_mojoScore_3735195.png",
        "date": "2025-11-28 10:05:12",
        "description": "Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 155,
    "sid": "10039335",
    "stock_news_url": "https://www.marketsmojo.com/news/akums-drugs-pharmaceuticals-10039335"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "13 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

2026-02-02 00:57:21

Recent Price Performance and Market Context

Akums Drugs has outperformed its sector and the Sensex benchmark in the short term. Over the past week, the stock appreciated by 4.90%, while the Sensex declined by 1.00%. Year-to-date, the stock has marginally declined by 1.99%, yet this is still better than the Sensex's 5.28% fall. The stock's intraday high on 01-Feb reached ₹454.95, a 3.35% increase from the previous close, signalling strong buying interest during the session.

Notably, the stock has been trading above its 5-day, 20-day, and 50-day moving averages, indicating positive short- to medium-term momentum. However, it remains below its 100-day and 200-day moving averages, suggesting that longer-term trends have yet to fully turn bullish. Liquidity remains adequate...

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-02-01 10:10:22

Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Akums Drugs & Pharmaceuticals Ltd Faces Technical Momentum Shift Amid Bearish Signals

2026-01-27 08:03:44

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some mildly bullish signals on weekly MACD and KST indicators, the overall technical landscape remains cautious, reflecting the stock’s underperformance relative to the broader market and sector benchmarks.

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-01-21 10:10:53

Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 21 January 2026, providing investors with the latest view of the stock’s position.

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-01-10 10:10:49

Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2025-12-30 10:10:31

Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Akums Drugs & Pharmaceuticals: Technical Momentum Shifts Amid Mixed Market Signals

2025-12-23 08:18:58

Akums Drugs & Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent price movements and technical parameters suggest a transition from a mildly bearish stance to a more sideways trend, highlighting a period of consolidation amid fluctuating investor sentiment.

Read full news article

Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-12-19 10:10:20

Akums Drugs has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. The pharmaceutical company’s recent assessment highlights a complex interplay of valuation appeal, financial pressures, and technical signals, set against a backdrop of subdued sector performance and market capitalisation constraints.

Read full news article

Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-11-28 10:05:12

Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News